Compare Expeditors International of Wshngtn Inc (EXPD) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Moderna, Inc. — how do they compare? Expeditors International of Wshngtn Inc trades at $193.74 (market cap $24.81B), while Moderna, Inc. trades at $197.4 (market cap $78.44B). The key difference: Moderna, Inc. is far larger — about 3.2× Expeditors International of Wshngtn Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.85% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and Moderna, Inc. for 59 Days on average.
| EXPD | MRNA | |
|---|---|---|
Market Cap | $24.81B | $78.44B |
Volume | 832,787 | 14,597,511 |
Sector | Industrials | Health |
52-Week High | $194.12 | $203.46 |
52-Week Low | $113.13 | $22.36 |
Typical Hold Time | 43 Days | 59 Days |
Enterprise Value | $24.34B | $74.59B |
Dividend Yield | 0.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $193.71, up 1.0% with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with 42.6% ROE and has beaten earnings estimates for three consecutive quarters. Recent news highlights efficiency initiatives and resilient airfreight demand as positive catalysts. Institutional activity shows mixed positioning with some major funds increasing stakes while others reduced exposure.
While EXPD shows strong operational metrics and earnings momentum, the stock trades above analyst consensus target of $174.86, suggesting limited near-term upside. Risks include competitive pressures and potential freight market volatility. The company's focus on efficiency and shareholder returns provides stability, but valuation remains elevated at 27.78 P/E ratio.
Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.
Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
